Detection of IDH mutations in cerebrospinal fluid: A discussion of liquid biopsy in neuropathology
Open Access
- 17 September 2020
- journal article
- Published by Heighten Science Publications Corporation in Archives of Pathology and Clinical Research
- Vol. 4 (1), 011-023
- https://doi.org/10.29328/journal.apcr.1001018
Abstract
Isocitrate dehydrogenase (IDH) mutations are a common event in secondary glioblastoma multiforme and lower-grade adult infiltrative astrocytomas and independently confer a better prognosis [1,2]. These are highly conserved mutations during glioma progression and thus also a useful diagnostic marker amenable to modern molecular sequencing methods. These mutations can even be detected in sites distant from the primary tumour. We use an illustrative case of a patient with radiologically suspected recurrent astrocytoma and negative histology, but positive IDH-mutated tumour DNA detected within CSF. Our results demonstrated the usefulness of liquid biopsy for recurrent glioma within the context of equivocal or negative histopathological results, whilst also showing the ability to detect a de-novo IDH-2 mutation not present in the previous resection. Building on this ‘proof-of-concept’ result, we also take the opportunity to briefly review the current literature describing the various liquid biopsy substrates available to diagnose infiltrative gliomas, namely the study of circulating tumour DNA, circulating tumour cells, and extracellular vesicles. We outline the current challenges and prospects of liquid biopsies in these tumours and suggest that more studies are required to overcome these challenges and harness the potential benefits of liquid biopsies in guiding our management of gliomas.Keywords
This publication has 67 references indexed in Scilit:
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences of the United States of America, 2013
- BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular VesiclesMolecular Therapy Nucleic Acids, 2013
- Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapyNature Medicine, 2012
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expressionNeuro-Oncology, 2012
- IDH1andIDH2Mutations in GliomasThe New England Journal of Medicine, 2009
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkersNature, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- O6-Methylguanine-DNA methyltransferase inactivation and chemotherapyBritish Medical Bulletin, 2008